Diroximel fumarate (Vumerity^®), an orally administered disease-modifying drug (DMD), expands the available treatment options for adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary progressive MS. It demonstrates bioequivalence to dimethyl fumarate and was developed to provide similar clinical benefits, but with an improved gastrointestinal (GI) tolerability profile. In RRMS patients who are treatment-naïve or were previously treated with interferon-β or glatiramer acetate, diroximel fumarate reduces annualized relapse rates, with most patients experiencing no relapses during treatment, and reduces the formation of new MS-associated brain lesions. Diroximel fumarate has an acceptable tolerability profile that is consistent with that of dimethyl fumarate, albeit with a significantly lower rate of GI adverse events.

Diroximel fumarate (Vumerity ^®) 是一种口服的疾病缓解药物 (DMD)，它为患有复发型多发性硬化症 (MS) 的成人扩大了可用的治疗选择，包括临床孤立综合征、复发缓解型 MS (RRMS) 和活动性继发进展型 MS。它证明了与富马酸二甲酯的生物等效性，并被开发用于提供类似的临床益处，但具有改善的胃肠道 (GI) 耐受性特征。在未接受过治疗或之前接受过干扰素-β或醋酸格拉替雷治疗的 RRMS 患者中，富马酸地罗西美降低了年复发率，大多数患者在治疗期间没有复发，并减少了新的 MS 相关脑损伤的形成。Diroximel fumarate 具有可接受的耐受性，与富马酸二甲酯一致，